Loading...
Aspirin use may reduce the risk for developing colorectal cancer. After surgery and adjuvant therapy, aspirin may also reduce the risk for colorectal cancer recurrence.
Investigators evaluated the more specific cyclooxygenase-2 inhibitor, celecoxib, added to standard adjuvant therapy for stage III colon cancer in the Cancer and Leukemia Group B/Southwest Oncology Group (SWOG) 8702 phase 3 trial. Patients with resected stage III colon cancer were randomized to receive 3 or 6 months of mFOLFOX6 and either placebo or celecoxib (400 mg orally daily) for 3 years. The primary endpoint was disease-free survival. The trial was also part of an international collaboration assessing the noninferiority of 3 versus 6 months of adjuvant chemotherapy.
Of 25…